Bullish micro-cap thesis on GRI Bio citing positive Phase 2a IPF data, high analyst price targets, Nasdaq compliance fix, and a potential Phase 2b catalyst or buyout.
GRI — LONG The author argues GRI Bio is a high-risk micro-cap with a large gap between its ~$0.28 price and analyst targets of $10-$30. The claimed mechanism is positive Phase 2a data (Jan 2026) for lead drug GRI-0621 in IPF, which reportedly stopped lung function decline in twice as many patients versus standard care. An $8 million December offering is said to resolve Nasdaq minimum-equity compliance, and the next Phase 2b could be a catalyst for a big pharma buyout or partnership. The author explicitly flags this as a high-risk micro-cap play.
They just dropped additional Phase 2a data (Jan 2026) for their lead drug, GRI-0621, which treats lung scarring (IPF). The results weren't just "okay"—the drug actually showed it could stop lung function decline in twice as many patients compared to standard care.
This Reddit post, published January 10, 2026, features u/Richoffpurp discussing GRI. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Richoffpurp · Tickers: GRI